Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Autoimmune Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD146 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD146 ECD-Fc Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View CD146 Products |
| Gene Delivery | CD146 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for cell-based binding assays. |
View CD146 Products |
| Benchmark Ab | Anti-CD146 Recombinant mAb (PRX003 sequence) Recombinant positive control for blocking/binding assays. |
View CD146 Products |
| Validator | CD146 siRNA Set For knockdown verification. |
View CD146 Products |
| Related Target A | LAMA4 (Laminin alpha 4) Direct ligand of CD146. Critical for blood-brain barrier (BBB) migration and vascular stability assays. |
View LAMA4 Products |
| Related Target B | VEGFR2 Co-receptor network partner. Essential for angiogenesis synergy screening. |
View VEGFR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval | Human/Mouse/Cyno ortholog proteins available with >95% purity |
| CD146-Laminin Interaction Blocking | High-purity LAMA4 and CD146 ECD-Fc for robust ELISA/SPR screening |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CD146/MCAM R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD146 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs) and bispecific antibodies targeting solid tumors. As first-generation therapies reach the clinic, the next wave of R&D is targeting the disruption of CD146-laminin 411 interactions in neuro-inflammatory diseases and overcoming therapy-resistant vascularized tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ADC | Academic/Biotech Consortiums | Melanoma, Triple-Negative Breast Cancer (TNBC) | Internalization Assay (Need high-purity ECD-Fc) |
| mAbs (Blocking) | Prothena, CAS (Institute of Biophysics) | Multiple Sclerosis, Psoriasis, Angiogenesis | Ligand Blocking Validation (Need LAMA4 & CD146 interaction assays) |
| CAR-T | Translational Oncology Labs | Sarcomas, Gliomas | Target Density & Cross-reactivity (Need Lentivirus for Stable Cell Lines) |